Feeds:
Posts
Comments

Posts Tagged ‘MEDICAL NEWS TODAY’

MEDICAL NEWS TODAY: The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. READ MORE>

The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article in The Journal of the National Cancer Institute.

if the biomarker is affected by a non-cancer disease, its utility for cancer detection may be compromised. For example, the prostate-specific antigen (PSA) biomarker, which is used to detect prostate cancer, is also elevated in benign prostatic hyperplasia.

Read Full Post »

MEDICAL NEWS TODAY: Men with PSA levels in the “uncertainty zone” – that is, readings between 2 and 4 – may be more accurately diagnosed with a different kind of PSA test, using proenzyme (p2PSA). READ MORE>

Read Full Post »

MEDICAL NEWS TODAY: Men who have a baseline PSA value of 10 or higher the first time they are tested are up to 11 times more likely to die from prostate cancer than are men with lower initial values. READ MORE>

Read Full Post »

MEDICAL NEWS TODAY: In trying to better predict a patient’s response to chemotherapy, a team of investigators at the State University of New Jersey has identified a way to better manipulate a gene product to cause cancer cells to die. READ MORE>

Read Full Post »

MEDICAL NEWS TODAY: There is insufficient evidence to support population-wide screening for prostate cancer using the PSA test, conclude two papers published on bmj.com (British Medical Journal) today. READ MORE>

Read Full Post »

MEDICAL NEWS TODAY: Nearly of 300 of the world’s leading researchers focused on the problem of prostate cancer are meeting in Nevada to discuss the latest scientific data and breakthroughs in prostate cancer. READ MORE>

Read Full Post »

MEDICAL NEWS TODAY: A phase 3 clinical trial of the investigational drug MDV3100 for advanced prostate cancer has just begun in the US. READ MORE>

Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with .

Read Full Post »

Older Posts »